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AbstrACt 
Purpose Limited published data exist on the clinical 
epidemiology of atrial fibrillation (AF) in South Asia 
including India. Most of the published data are from the 
Western countries and the Far East. The Kerala AF registry 
was initiated to collect systematic, prospective data on 
clinical characteristics, risk factors, treatment pattern 
and outcomes of consecutive AF patients who consulted 
cardiologists across the state of Kerala, India.
Participants All newly diagnosed and previously reported 
patients aged ≥18 years with documented evidence of AF 
on ECG were included. Patients with transient AF due to 
infection, acute myocardial infarction, alcohol intoxication, 
metabolic abnormalities and AF seen in postoperative 
cases and critically ill patients with life expectancy less 
than 30 days were excluded.
Findings to date A total of 3421 patients were recruited 
from 53 hospitals across Kerala from April 2016 to April 
2017. There were 51% (n=1744) women. The median age 
of the cohort was 65 (IQR 56–74) years. Hypertension, 
diabetes mellitus and dyslipidaemia were present in 
53.8%, 34.5% and 42.2% patients, respectively. Chronic 
kidney disease was observed in 46.6%, coronary artery 
disease in 34.8% and heart failure (HF) in 26.5% of 
patients. Mean CHA
2DS2-VASc score of the cohort was 
2.9, and HAS-BLED score was 1.7. Detailed information 
of antithrombotic and antiarrhythmic drugs was collected 
at baseline and on follow-up. During 1-year follow-up, 
443 deaths (12.9%) occurred of which 332 (9.7%) were 
cardiac death and 63 (1.8%) were due to stroke. There 
were 578 (16.8%) hospitalisations mainly due to acute 
coronary syndrome, arrythmias and HF.
Future plans Currently, this is the largest prospective 
study on AF patients from India, and the cohort will be 
followed for 5 years to observe the treatment patterns 
and clinical outcomes. The investigators encourage 
collaborations with national and international AF 
researchers.
trial registration number CTRI/2017/10/010097.
IntroduCtIon
Atrial fibrillation (AF) is the most common 
cardiac arrhythmia seen in clinical prac-
tice, and it is an independent risk factor for 
death in men and women.1 AF is associated 
with a fivefold increase in stroke risk and 
25%–30% stroke seen in adults are associated 
with this arrhythmia.2 3 While AF is a global 
problem, much of the available epidemio-
logical data are from the Western countries 
and the Far East.4 Limited published data 
strengths and limitations of this study
 ► Currently the largest prospective cohort of atrial 
fibrillation (AF) patients from South Asia.
 ► Fifty-three participating centres recruited patients 
from government hospitals, teaching institutions, 
private and corporate hospitals located both in ur-
ban and rural areas of Kerala state.
 ► The collected data included physical examination, 
electrocardiographic and echocardiographic find-
ings, laboratory investigations of blood sample and 
follow-up outcomes.
 ► Although the study is limited to Kerala, results may 
provide an indication of future epidemiology of AF in 
India as Kerala is ahead of other states in epidemi-
ological transition.
 ► However, these registry data may not reflect the true 
incidence or prevalence of AF in the state, since it is 
a hospital-based study.  on A
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exist on the clinical epidemiology of AF in South Asia 
(see online supplementary table 1). 
Kerala, the southernmost state of India, is witnessing 
an increase in the burden of patients with AF due to 
increased longevity, higher prevalence of cardiovas-
cular risk factors and comorbid conditions.5 6 However, 
the treatment and care offered to these patients is 
generally perceived to be suboptimal especially with 
regard to stroke prevention strategy. Vitamin K antago-
nists (eg, warfarin) are the commonly used oral antico-
agulants, but monitoring of international normalised 
ratio (INR) is highly erratic,7 and often low target 
values (Internatioal normalized ratio (INR) <2.0) is 
accepted by the physicians. Nevertheless, there is lack 
of information on the existing treatment strategy as 
well as how it compares with the guideline recom-
mended management of AF.8 The Kerala AF registry 
aims to provide systematic, prospective data on clin-
ical characteristics, risk factors, treatment pattern and 
outcomes of consecutive AF patients who consulted 
cardiologists across Kerala. The registry was instituted 
under the auspices of Cardiological Society of India, 
Kerala Chapter (CSI-K).
Cohort desCrIPtIon
All newly and previously diagnosed patients aged ≥18 
years with documented evidence of AF on ECG were 
included in the study from April 2016 to April 2017. The 
study was initiated in April 2016, and 53 hospitals across 
the state of Kerala have contributed patients during the 
1 year enrolment period. In order to get the best repre-
sentative data from both rural and urban areas of the 
whole state, patients were recruited from government, 
private and corporate hospitals from different regions of 
Kerala. At each site, one investigator and a study coordi-
nator handled the patient recruitment. Kerala state has 
an area of 38 863 km2 and a population of 37.3 million.9 
For better coordination of the study, Kerala was divided 
in to three zones: south, middle and north with 20 partic-
ipating sites from south, 21 from middle and 12 from 
north zone (figure 1). The three zones had one zonal 
coordinator each, who supervised the study conduct at 
their respective zones.
Patients with transient AF due to causes like acute 
myocardial infarction, infection, alcohol intoxication, 
metabolic abnormalities, postoperative cases and criti-
cally ill patients with life expectancy less than 30 days were 
excluded. Each patient was enrolled in the registry after 
examination by the cardiologist(s) of the participating 
centre. Detailed medical history, physical examination 
and laboratory investigation including echocardiography 
was done, and the results were entered in the case report 
form (CRF).
Patients were classified into AF with valvular heart 
disease (AFVHD) and non-valvular AF (NVAF). 
AFVHD is defined as those cases associated with 
mitral stenosis, prosthetic valve implantation and 
mitral valve repair. These patients were further cate-
gorised as rheumatic or non-rheumatic and subcat-
egorised as mitral, aortic or combined based on the 
clinical and echocardiographic findings. Out of the 
914 AFVHD patients, 80.2% were rheumatic and 
19.8% were non-rheumatic. The higher proportion 
of rheumatic aetiology seen in AFVHD patients could 
be due to the higher prevalence of rheumatic heart 
disease in Kerala. AF rhythm type was classified into 
paroxysmal, persistent and permanent. Stroke risk 
was estimated using the Congestive heart failure, 
Hypertension, Age≥75, Diabetes mellitus, Previous 
Stroke, Vascular disease, age 65 to 74, Sex category 
(CHA2DS2-VASc)
10 score and bleeding risk using the 
Hypertension, Abnormal renal/ liver function, stroke, 
bleeding history or predisposition, labile INR, Elderly 
age>65 years, Drugs/ alcohol (HAS-BLED) score.11 
Detailed data on treatment, mainly stroke prophy-
laxis regimen, antiarrhythmic drug treatment, pace-
maker implantation, AF ablation, surgery for AF and 
device closure of left atrial appendage and treatment 
Figure 1 Map of Kerala showing the distribution of study 
sites.
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for comorbidities, were collected at the time of 
recruitment and follow-up. Data on major outcomes 
including death (all-cause as well as cardiac) and 
need for hospitalisation were documented at 30 days, 
6 months and 1 year. The cohort will be followed up 
annually for 5 years through clinic visit or by tele-
phonic contact. Five-year follow-up will be completed 
by April 2022.
Patient and public involvement
Patients were not involved in the design of the study. 
Once the patients were recruited in the study, they were 
explained the health consequences of AF and the need 
for stroke prevention and arrhythmia management by the 
cardiologist.
statistical analysis
Data were entered using EpiData Entry 3.1 version soft-
ware12 and analysed using R software13 and Microsoft 
Excel package.
Findings to date
A total of 3421 patients were recruited between 4 April 
2016 and 3 April 2017. Follow-up at 30 days, 6 months and 
1 year was completed by April 2018. NVAF constituted 
73.3% (n=2507) and AFVHD 26.7% (n=914) of patients. 
There were 49% (n=1677) men and 51% (n=1744) 
women. The median age of the cohort at recruitment was 
65 years (IQR 56–74). The median body mass index of 
the study population was 24.22 kg/m2 (IQR 21.6–26.5). 
Patient characteristics and prevalence of risk profile of 
the cohort at the time of recruitment is given in table 1. 
AFVHD was more common in women compared with 
men (67.4% vs 32.6%) (p<0.001), whereas NVAF was 
more common in men (55% vs 45%) (p<0.001). Hyper-
tension, diabetes mellitus and dyslipidaemia were present 
in 53.8% (n=1840), 34.5% (n=1179) and 42.2% (n=1443) 
cases of AF, respectively. History of rheumatic fever was 
present 17.7% (n=607) of patients. Chronic kidney disease 
(creatinine clearance below 60 mL/min)14 was observed 
in 46.6% (n=1597) of patients, coronary artery disease in 
Table 1 Baseline characteristics at the time of recruitment by gender
Parameters
Men (n=1677)
n (%)
Women (n=1744)
n (%)
Total (n=3421)
n (%)
Age (in years) (median and IQR) 65 (56–74) 65 (56–74) 65 (56–74)
Height (cm) (mean±SD) 165 (±7.2) 155 (±7.0) 160.00 (±8.7)
Weight (kg) (mean±SD) 66.3 (±11) 58.4 (±10.8) 62.31 (±11.6)
CHA2DS2-VASc score (mean±SD) 2.60 (±1.7) 3.20 (±1.7) 2.91 (±1.7)
HAS-BLED score (mean±SD) 1.79 (±1.3) 1.59 (±1.2) 1.69 (±1.3)
Chronic heart failure 472 (28.2) 432 (24.9) 904 (26.5)
Hypertension 936 (55.8) 904 (51.8) 1840 (53.8)
Diabetes 611 (36.5) 568 (32.5) 1179 (34.5)
Stroke/TIA or systemic embolism 246 (14.7) 265 (15.3) 511 (14.9)
Coronary artery disease 764 (45.5) 423 (24.3) 1187 (34.8)
Dyslipidaemia 760 (45.3) 683 (39.1) 1443 (42.2)
Chronic kidney disease 247 (14.8) 104 (5.9) 351 (10.3)
Chronic liver disease 45 (2.7) 23 (1.3) 68 (1.9)
Respiratory disease 371 (22.8) 343 (19.7) 714 (17.7)
Congenital heart disease 37 (2.3) 43 (2.5) 80 (2.4)
Gastrointestinal bleed 77 (4.6) 46 (2.6) 123 (3.6)
Thyroid disease 228 (13.6) 357 (20.5) 585 (17.1)
NYHA Class I and II 1375 (81.9) 1443 (82.6) 2818 (82.4)
NYHA Class III and IV 299 (17.8) 302 (17.3) 601 (17.6)
Paroxysmal AF 706 (42.1) 643 (36.8) 1349 (39.4)
Persistent AF 261 (15.5) 230 (13.1) 491 (14.4)
Permanent AF 709 (42.2) 872 (50.0) 1581 (46.2)
AF with valvular heart disease 305 (18.8) 612 (34.4) 917 (26.7)
Non-valvular AF 1373 (81.9) 1131 (65.5) 2504 (73.2)
Cardiomyopathy 164 (9.7) 146 (8.4) 310 (9.1)
AF, atrial fibrillation; NYHA, New York Heart Association; TIA, transient ischaemic attack.
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34.8% (n=1187) and heart failure in 26.5% (n=904) of 
patients. Mean CHA2DS-VASc score of the cohort was 2.9, 
and HAS-BLED score was 1.7. Daily use of medication at 
baseline and at 1-month follow-up are reported in table 2. 
A total of 443 (12.9%) deaths and 578 (16.8 %) hospi-
talisation occurred during 1-year follow-up (table 3). 
In all age groups, majority of hospitalisation and death 
occurred during the first half of follow-up period (61.8% 
and 62.3%, respectively) than the second half (figures 2 
and 3). In the Indian Heart Rhythm Society-Atrial Fibril-
lation registry,7 the mortality and the hospitalisation rates 
were 6.5% and 8%, respectively. In the EURObservational 
Research Programme Atrial Fibrillation registry,15 1-year 
mortality was 5.7%.
Table 2 List of medication at baseline and first follow-up (30 days)
Medication at baseline Medication at first follow-up
Men n (%) Women n (%) Total n (%) Men n (%) Women n (%) Total n (%)
Warfarin 501 (29.8) 660 (37.8) 1161 (34) 769 (45.9) 975 (55.9) 1744 (50.9)
Acitrom 134 (8.0) 148 (8.5) 282 (8.2) 221 (13.1) 225 (12.9) 446 (13.1)
Phenindione 7 (0.4) 2 (0.1) 9 (0.2) 2 (0.1) 1 (0.05) 3 (0.9)
Dabigatran 31 (1.8) 15 (0.9) 46 (1.3) 58 (3.5) 42 (2.4) 100 (2.9)
Apixaban 11 (0.7) 7 (0.40) 18 (0.5) 38 (2.3) 19 (1.1) 57 (1.6)
Rivaroxaban 3 (0.17) 1 (0.06) 4 (0.1) 21 (1.2) 13 (0.74) 34 (1.0)
ASA 382 (22.7) 285 (16.1) 667 (19.5) 524 (31.3) 390 (22.3) 914 (26.7)
Clopidogrel 334 (19.9) 245 (14.0) 579 (16.9) 517 (30.8) 411 (23.5) 928 (27.1)
Prasugrel 2 (0.1) 3 (0.17) 5 (0.14) 2 (0.1) 3 (0.2) 5 (0.1)
Ticagrelor 2 (0.1) 1 (<0.1) 3 (0.1) 9 (0.5) 2 (0.1) 11 (0.3)
Amiodarone 138 (8.2) 116 (6.6) 254 (7.4) 265 (15.8) 241 (13.8) 506 (14.8)
Propafenone 4 (0.2) 3 (0.1) 7 (0.2) 2 (0.1) 3 (0.2) 5 (0.1)
Flecainide 8 (0.5) 9 (0.5) 17 (0.5) 6 (0.4) 10 (0.6) 16 (0.4)
Sotalol 2 (0.11) 0 2 (0.1) 3 (0.2) 0 3 (0.9)
Beta blockers 541 (32.2) 519 (29.7) 1060 (30.9) 840 (50.1) 786 (45.0) 1626 (47.5)
ACE inhibitors 97 (5.7) 77 (4.4) 174 (5.1) 163 (9.7) 116 (6.6) 279 (8.1)
ARB 167 (9.9) 246 (14.1) 413 (12.0) 245 (14.6) 328 (18.8) 573 (16.7)
Digoxin 296 (17.6) 466 (26.3) 762 (22.2) 424 (25.2) 621 (35.6) 1045 (30.5)
ARB, angiotensin receptor blockers; ASA, acetyl salicylic acid (aspirin).
Table 3 Death and hospitalisation at different time periods
Events
Recruitment to 
1 month 1–6 months 6 months–1 year Total in 1 year (%)
Death (all causes) 69 207 167 443 (12.9)
  Cardiac 54 157 121 332 (9.7)
  Stroke 11 21 31 63 (1.8)
  Other 4 29 16 49 (1.4)
Hospitalisation (all causes) 147 210 221 578 (16.9)
  Stroke 15 12 24 51 (1.5)
  Transient ischaemic attack 3 3 6 12 (0.4)
  Acute coronary syndrome 42 94 66 202 (5.9)
  Arrythmia 29 56 90 175 (5.1)
  Heart failure 34 23 17 74 (2.2)
  Systemic embolism other than stroke 3 4 4 11 (0.3)
  Gastrointestinal bleed 10 5 8 23 (0.7)
  Intracranial bleed 1 4 2 7 (0.2)
  Minor bleed 10 9 4 23 (0.7)
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Comparison with other published AF cohorts
Literature review showed three studies on patients with AF 
from South Asia, of which two are prospective cohort studies. 
The Indian Heart Rhythm Society-Atrial Fibrillation (IHRS-
AF)7 registry, with 1537 patients from 12 cities across India 
was the only available study exclusively on Indian patients with 
AF with study sites predominantly from secondary or tertiary 
referral cardiac centres. Even though the multinational 
cross-sectional study, the Real-Life Global Survey Evaluating 
Patients with Atrial Fibrillation16 17 had an Indian cohort of 
301 patients, all were recruited from private healthcare institu-
tions located in 15 urban areas. The Randomized Evaluation 
of Long-Term Anticoagulation Therapy18 was a prospective 
registry on patients with AF presenting to the emergency 
department in 46 countries including 2536 Indian patients 
from 22 hospitals in India. The Kerala AF Registry is the 
largest prospective cohort of patients with AF from India.
Unique aspects of the study include close collab-
oration of a wide range of contributing centres and 
systematic collection of outcome data. The registry 
recruited patients from government hospitals, 
teaching institutions, private and corporate hospitals 
located both in urban and rural areas of Kerala state. 
This has enabled the cohort to have patients from 
different socioeconomic backgrounds and lifestyle. 
Furthermore, many registries globally are sponsored 
by pharmaceutical or device companies, and the data 
collected may be influenced by the focus on patients 
with AF treated by their drugs or devices, leading to 
the possibility of selection bias.19 This study, however, 
has been sponsored by the professional association 
of cardiologists in the state, which is the CSI-K. Many 
published AF registries7 16–24 (see online supple-
mentary tables 1 and 2) have emphasised the need 
for adherence to the evidence-based treatment for 
reducing the stroke risk and overall mortality. Even 
though multiple AF databases are available from many 
countries that focus on various aspects of AF, there has 
been lack of coordination between these registries. 
An International Collaborative Partnership for the 
Study of Atrial Fibrillation, a worldwide partnership 
for investigators and countries has been initiated to 
capture all types of treatment patterns offered to the 
ever increasing population of patients with AF.25 The 
global burden of AF is likely to grow in an epidemic 
proportion as observed by the World Heart Federa-
tion.26 Although this phenomenon is observed from 
high-income countries,27–29 the clinical observations 
indicate the signal for a steady increase in the burden 
of patients with AF in India too.30 Currently, the avail-
able data from India have been inadequate to provide 
exact prevalence, morbidity, mortality and standard 
of care of patients with AF. Furthermore, the existing 
studies reveal lower usage of oral anticoagulants for 
stroke prevention in patients with AF. India being a 
large country with interstate variations in terms of 
epidemiology of diseases and other health indicators, 
a state-wide collection and compilation of data seem 
to be the ideal way for generating national data.31 The 
Kerala AF registry was therefore initiated as a state-
wide collection of data on patients with AF who seek 
medical advice, which could provide more informa-
tion about the clinical profile, sociodemographic 
characteristics and existing standard of treatment for 
patients with AF and how it differs from national and 
global data.
ethical considerations
The study was conducted according to the ethical 
guidelines of Indian Council of Medical Research 
and as per the ethical principles specified in Decla-
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a secure data base and only deidentified information 
were used for analysis.
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